The positive opinion handed to UK-based biotech firm, Provexis, linking a tomato extract and blood circulation is held up as an example of all that can go right with the process.
“I think it’s because it is specific about the claim, looks at the correct target population and the evidence shows a cause and effect,” Berryman says. “If you get those things right you will get the claim approved.”
Berryman highlights the importance of trial design and development of biomarkers such as vascular elasticity for cholesterol area that better demonstrate the effects of particular nutrients such as fibre on health.
Berryman's colleague, Mary Gilsenan, will take part in a round-table discussion at the NutraIngredients Health Claims 2010 conference to be held in Brussels tomorrow. Other speakers include Unilever, analyse&realise, Cantox, academics, industry groups, lawyers and market experts. For more information and last-minute registrations, please click here .